Aligos therapeutics to present nonclinical and clinical data for its chronic hepatitis b and nash portfolio at aasld's the liver meeting® 2022

South san francisco, calif., oct. 21, 2022 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at the liver meeting® (november 4-8, 2022), hosted by the american association for the study of liver diseases (aasld).
ALGS Ratings Summary
ALGS Quant Ranking